Skip to main content

Spinraza FDA Approval History

FDA Approved: Yes (First approved December 23, 2016)
Brand name: Spinraza
Generic name: nusinersen
Dosage form: Injection
Company: Biogen Inc.
Treatment for: Spinal Muscular Atrophy

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Development timeline for Spinraza

DateArticle
Dec 23, 2016Approval FDA Approves Spinraza (nusinersen) for Spinal Muscular Atrophy
Oct 28, 2016Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Sep 26, 2016Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy

See also

Spinraza (nusinersen) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer